Utah Lets an Algorithm Write Acne Scripts Without a Doctor

A New Standard of Care

Nolla Health announced Monday that its Nolla Derm app has been granted authority in Utah to issue initial medical prescriptions without a human doctor writing them. This is the first time an artificial intelligence system has received this specific power in the United States. It is not a limited beta test for tech enthusiasts or a distant sci-fi scenario. It is a live clinical pathway for residents aged 18 and older who can sign up for a monthly fee of $4.99.

The mechanism is deceptively simple on the surface. Patients complete a 10 to 15-minute intake questionnaire and submit a face scan. The AI then analyzes the skin, generates a numerical severity score, and selects a treatment from a pre-approved list of eight topical options. If the algorithm is confident, the prescription goes straight to a pharmacy or the patient's home. If it is not, the case is routed to a licensed physician. This binary outcome, either automated care or human referral, defines the new frontier of digital dermatology.

The Phased Autonomy Model

The rollout is structured with a safety net that tightens as the system gains experience. During the first stage, which covers the initial 100 enrolled patients, every single prescription generated by the AI must pass through a physician's review before it is sent to a pharmacy. This ensures that human oversight is absolute at the start. The goal is to validate the AI's accuracy in real-world conditions before loosening the reins.

Once the first 100 patients are completed, the program moves to a second stage involving the next 400 patients. Here, the AI sends prescriptions directly to pharmacies without prior human sign-off. Instead, a physician reviews the decisions on a weekly basis after the fact. This shift from pre-approval to post-audit is a critical step in reducing friction for patients while maintaining a layer of professional accountability. It is a calculated risk that relies on the system's proven consistency.

After the first 500 patients are processed, the oversight model becomes even more streamlined. Physician involvement shifts to a monthly audit that covers no fewer than one in ten prescriptions issued. This is the most autonomous phase of the pilot, where the AI operates with minimal direct human interference. The state of Utah has authorized this gradual release of control, betting on the technology's reliability to handle common dermatological issues efficiently.

Regulatory Green Light

This authorization comes from the Utah Office of Artificial Intelligence Policy, a division of the Utah Department of Commerce. The office has created a specific regulatory sandbox that allows companies to test AI products under relaxed rules. Zachary Boyd, the director of this office, described the move as a narrow exception carved out for Nolla Health. This is not a blanket approval for all AI medical practices, but a targeted pilot that sets a precedent for how states can integrate advanced technology into healthcare delivery.

The pilot program is set to run for one year, with the option to renew for up to two more years at the state's discretion. This temporary window allows regulators to monitor the system's performance, safety, and patient outcomes closely. It provides a controlled environment to gather data on how AI-driven prescriptions affect patient health and healthcare costs. The state is essentially running a large-scale experiment with real patients and real medications.

The legal framework is specific and limited. Prescriptions issued under this pilot carry a clinician's name, even though no human professional wrote them. This detail underscores the legal and ethical complexities of AI in medicine. The system is operating within a defined scope, restricted to pre-approved topical treatments for acne. It cannot generate open-ended prescriptions or diagnose conditions outside its designated parameters. This restriction is crucial for maintaining safety and regulatory clarity.

Accuracy and Limitations

Nolla Health claims that licensed clinicians agree with the AI's treatment recommendations in more than 96% of real-world cases. The disagreements that do occur are limited to minor adjustments, such as the strength of the topical medication. This high level of concordance suggests that the AI is capable of matching human clinical judgment for common acne treatments. However, the 4% of cases where they differ is where the complexity lies.

The system is explicitly designed to exclude patients with severe acne, pregnancy, or other conditions that fall outside the pilot's scope. These individuals are referred to a physician for comprehensive care. This triage mechanism is essential for ensuring that patients with complex or high-risk conditions receive the nuanced care that an algorithm cannot provide. It acknowledges the limits of current AI technology in handling multifaceted medical situations.

The use of pre-approved topical options further limits the scope of the AI's decision-making. It does not have the freedom to prescribe systemic medications or novel therapies. This constraint reduces the potential for harm but also limits the range of treatments available to patients. The AI is a tool for routine care, not a substitute for comprehensive medical evaluation. Patients should understand that this service is for straightforward cases of acne, not for complex dermatological disorders.

The Broader Implications

The launch of Nolla Derm in Utah marks a significant milestone in the integration of AI into clinical practice. It is the first time an AI system has been authorized to issue initial prescriptions in the US. This sets a precedent for other states and other medical specialties to consider similar models. The success of this pilot will likely influence future regulatory frameworks for AI in healthcare.

The economic implications are also significant. By automating the prescription process for common conditions, Nolla Health aims to reduce the burden on physicians and lower healthcare costs. Patients can access care more quickly and conveniently, without the need for an in-person visit. This model could potentially expand to other chronic conditions, such as hypertension or diabetes, where routine management is key.

However, the ethical and legal questions remain. Who is liable if the AI makes a mistake? How are patient data and privacy protected? These are complex issues that will need to be addressed as AI becomes more prevalent in healthcare. The Utah pilot provides a valuable test case for these questions, offering real-world data to inform future policy decisions. The outcome will have far-reaching implications for the future of medicine.

What Patients Should Know

If you are a resident of Utah aged 18 or older with acne, you now have a new option for care. You can sign up for the Nolla Derm program for $4.99 a month. The process is simple: complete the questionnaire, submit your face scan, and wait for your prescription. If the AI is confident in its recommendation, you will receive your medication. If not, you will be referred to a doctor.

It is important to understand that this service is limited to specific topical treatments for acne. It is not a replacement for comprehensive medical care. If you have severe acne, are pregnant, or have other health conditions, you should consult with a physician. The AI is a tool for routine care, not a diagnostic expert. Always follow the advice of your healthcare provider and use any new service with caution.

The future of healthcare is increasingly digital and automated. Nolla Health's pilot in Utah is a step in that direction. It offers a glimpse into a world where AI can handle routine medical tasks, freeing up doctors to focus on more complex cases. Whether this model becomes the standard or remains a niche experiment is yet to be determined. But for now, it is a reality for thousands of Utah residents.